OPTIMIZING THE DESIGN AND ANALYSIS OF EXPERIMENTS ON COMBINATION THERAPY (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


OPTIMIZING THE DESIGN AND ANALYSIS OF EXPERIMENTS ON COMBINATION THERAPY (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2642 1992. Unique Identifier : AIDSLINE ICDB/92685171
Weinstein JN; Bunow B; Muenz LR; NCI, Bethesda, MD 20892

Abstract: We recently described new concepts and a computer program 'toolbox' called COMBO for analyzing data on combination therapy of cancer and AIDS. The COMBO approach includes (1) flexible choice of interaction models (including ones that take into account both efficacy and toxicity), (2) parametric and nonparametric statistical methods for hypothesis testing and estimation of confidence intervals, and (3) flexibility with respect to experimental design. We have used COMBO to analyze data on combinations that include doxorubicin, suramin, tumor necrosis factor, dipyridamole, AZT, ddI, ddC, CD4-pseudomonas exotoxin and HIV protease inhibitors, inter alia (Ann NY Acad Sci 616:367-84, 490-4, 1991; PNAS 87:8889-93, 1990). We have now focused on another practical aspect of the problem: given the large number of combinations that should, in principle, be tested, how can one reduce the number of data points required per combination? This has become a problem even for our experiments in vitro, let alone for testing in animals and in the clinic. Accordingly, the COMBO toolbox includes statistical methods that aid the investigator in designing more resource-efficient experiments.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Antineoplastic Agents, Combined/*THERAPEUTIC USE Antiviral Agents/*THERAPEUTIC USE Computer Simulation *Drug Therapy, Combination Human Neoplasms/*DRUG THERAPY *Software ABSTRACT

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapyantineoplasticagents,combined/KWDtherapeuticuseantiviralagents/KWDtherapeuticusecomputersimulationKWDdrugtherapy,combinationhumanneoplasms/KWDdrugtherapyKWDsoftwareabstract
921130
M92B0883

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .